Marvel Biosciences Management
Management criteria checks 4/4
Marvel Biosciences' CEO is Rod Matheson, appointed in Jul 2021, has a tenure of 3.5 years. total yearly compensation is CA$150.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.61% of the company’s shares, worth CA$181.05K. The average tenure of the management team and the board of directors is 3.5 years and 3.2 years respectively.
Key information
Rod Matheson
Chief executive officer
CA$150.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 3.5yrs |
| CEO ownership | 2.6% |
| Management average tenure | 3.5yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Oct 31 2024 | n/a | n/a | -CA$1m |
| Jul 31 2024 | n/a | n/a | -CA$2m |
| Apr 30 2024 | n/a | n/a | -CA$2m |
| Jan 31 2024 | n/a | n/a | -CA$3m |
| Oct 31 2023 | n/a | n/a | -CA$3m |
| Jul 31 2023 | CA$150k | CA$150k | -CA$2m |
| Apr 30 2023 | n/a | n/a | -CA$2m |
| Jan 31 2023 | n/a | n/a | -CA$2m |
| Oct 31 2022 | n/a | n/a | -CA$2m |
| Jul 31 2022 | CA$150k | CA$150k | -CA$3m |
| Apr 30 2022 | n/a | n/a | -CA$4m |
| Jan 31 2022 | n/a | n/a | -CA$4m |
| Oct 31 2021 | n/a | n/a | -CA$3m |
| Jul 31 2021 | CA$147k | CA$147k | -CA$3m |
| Apr 30 2021 | n/a | n/a | -CA$1m |
| Jan 31 2021 | n/a | n/a | -CA$1m |
| Oct 31 2020 | n/a | n/a | -CA$1m |
| Jul 31 2020 | CA$77k | CA$77k | -CA$956k |
Compensation vs Market: Rod's total compensation ($USD103.96K) is below average for companies of similar size in the Canadian market ($USD164.13K).
Compensation vs Earnings: Rod's compensation has been consistent with company performance over the past year.
CEO
Rod Matheson
3.5yrs
Tenure
CA$150,000
Compensation
Mr. J. Roderick Matheson, also known as Rod, serves as Chief Executive Officer & Director at Marvel Biosciences Corp. since June 14, 2021 and served as its President and serves as its Executive Chairman. H...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 3.5yrs | CA$150.00k | 2.61% CA$ 181.0k | |
| President | 3.5yrs | CA$150.00k | 11.16% CA$ 775.0k | |
| Chief Financial Officer | 2.9yrs | CA$82.50k | no data | |
| Corporate Secretary | 3.5yrs | no data | 1.44% CA$ 100.0k |
3.5yrs
Average Tenure
Experienced Management: MRVL's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 3.6yrs | CA$150.00k | 2.61% CA$ 181.0k | |
| President | 3.6yrs | CA$150.00k | 11.16% CA$ 775.0k | |
| Independent Director | 2.2yrs | CA$6.67k | 0.38% CA$ 26.3k | |
| Lead Independent Director | 3.6yrs | CA$10.00k | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Independent Director | 2.9yrs | CA$10.00k | no data |
3.2yrs
Average Tenure
Experienced Board: MRVL's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/12 14:59 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Marvel Biosciences Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|